Boston Scientific Corp. reports $5.14 billion revenue for quarter ended September 30, 2026, up 1.4%
Boston Scientific Corp. reported revenue of $5.14 billion for the quarter ended September 30, 2026, an increase of 1.4% from the same quarter a year earlier ($5.07 billion).
For the same period it posted net income of $580 million, down 23.2%, or $0.40 per diluted share (0.51 a year earlier).
That is a net margin of 11.3%.
On Sanad's AAOIFI Standard 21 screen, Boston Scientific Corp. is currently compliant: interest-bearing debt is 19.2% of market capitalisation (limit 30%), and impure income is 0.5% of revenue (limit 5%).
Is Boston Scientific Corp. halal?
See the full AAOIFI screening of Boston Scientific Corp.
See the full AAOIFI screening of Boston Scientific Corp.
Source: 10-Q filed with the U.S. Securities and Exchange Commission on November 2, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.